Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02567656 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
A Phase 1 study of Lymphoma, T-Cell, Peripheral and Lymphoma, T-Cell, Cutaneous, sponsored by Rhizen Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 8
- Study locations
NCT02567656: Completed Phase 1 study of Lymphoma, T-Cell, Peripheral and Lymphoma, T-Cell, Cutaneous, sponsored by Rhizen Pharmaceuticals.
NCT02567656 is a Phase 1 study of Lymphoma, T-Cell, Peripheral and Lymphoma, T-Cell, Cutaneous that has completed, run by Rhizen Pharmaceuticals. The registered enrollment target is 58 participants, below the 323-participant average among 6 other Lymphoma, T-Cell, Peripheral trials with a reported enrollment target (82% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02567656, a Phase 1 study of Lymphoma, T-Cell, Peripheral and Lymphoma, T-Cell, Cutaneous, has completed, sponsored by Rhizen Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.
Primary Outcome
Number of participants with Treatment-Related Adverse Events as Assessed by CTACE v4.0
Conditions Studied
Interventions
- DRUG RP6530
Study Locations (8)
California
- City of Hope - Duarte
- Chao Family Comprehensive Cancer Center University of California Irvine - Orange
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Karmanos Cancer Institute - Detroit
Colorado
- University of Colorado Cancer Center - Aurora
Georgia
- Emory University School of Medicine - Atlanta
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2015-09 |
| Est. Completion | 2018-12-10 |
| Phase | Phase 1 |
What the finished NCT02567656 record still lists
NCT02567656 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 323-participant average among 6 other Lymphoma, T-Cell, Peripheral trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Lymphoma, T-Cell, Peripheral appearing as the primary indexed condition, and to 1 intervention - of which RP6530 is the first listed.
NCT02567656 lists 8 locations in 6 states (California, Michigan, Colorado).
Frequently Asked Questions
What is clinical trial NCT02567656 about?
NCT02567656 is a clinical study titled "Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma". The purpose of this study is to evaluate the safety, PK and efficacy of RP6530, a dual PI3K delta/gamma inhibitor in patients with relapsed and refractory T-cell Lymphoma.
What is the current status of trial NCT02567656?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2015-09. Estimated completion is 2018-12-10.
What conditions does trial NCT02567656 study?
This clinical trial studies the following conditions: Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous.
What interventions are being tested in trial NCT02567656?
The interventions under investigation include: RP6530 (DRUG).
Who is sponsoring clinical trial NCT02567656?
This trial is sponsored by Rhizen Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02567656 being conducted?
This trial has 8 study locations across California, Colorado, Georgia, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, T-Cell, Peripheral
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
-
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)
ACTIVE NOT RECRUITING · Phase 1
-
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RECRUITING · Phase 3
-
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
COMPLETED
-
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia